Nov
12
2019
On demand

Meeting the scalability challenge of downstream viral vector purification

Sponsor
Meeting the scalability challenge of downstream viral vector purification

In the expanding field of gene and cell therapy, continuous flow ultracentrifugation is slowly revealing its ability to overcome downstream bottlenecks. Unlike the more well-known tube rotor designs, continuous flow zonal UCF offers a unique ability to dynamically use revolving zones at high speeds to provide a scalable and cost-effective process for the purification and concentration of viral vectors.

  • Understand the capabilities and benefits of continuous flow ultracentrifugation to purify and concentrate viral vectors (including AAV) in a predictable manner.
  • Assess the scalability and cost-effectiveness of solutions to downstream bottlenecks and gene therapy process development.
  • Discover what makes linear scalability possible with continuous flow ultracentrifugation.
  • Learn how to improve your product recovery and process time.

Seth Brittle
Seth Brittle
Process Engineer at Alfa Wassermann Separation Technologies
Sandra Merino
Sandra Merino
Global Project Director at Alfa Wassermann Separation Technologies
Xiaotong Fu
Xiaotong Fu
Senior Engineer, Downstream Bioprocess Development, Gene Therapies at Biogen Idec
George Todorov
George Todorov
Associate Director, Early Stage Process Development at Adverum Biotechnologies, Inc.

SPEAKERS

Seth Brittle
Seth Brittle
Process Engineer at Alfa Wassermann Separation Technologies
Sandra Merino
Sandra Merino
Global Project Director at Alfa Wassermann Separation Technologies
Xiaotong Fu
Xiaotong Fu
Senior Engineer, Downstream Bioprocess Development, Gene Therapies at Biogen Idec
George Todorov
George Todorov
Associate Director, Early Stage Process Development at Adverum Biotechnologies, Inc.

You might also like